Predictive Oncology (POAI) Announces Positive Results from Recent Study Utilizing AI To Predict Cancer Patient Outcomes, Up ~40%.
The AI driven drug discovery company, Predictive Oncology, Inc. (POAI) announced positive results from a recent study whose purpose was to determine if POAI could utilize its AI capabilities and machine learning (ML) models to more accurately predict short- and long-term survival outcomes amongst ovarian cancer patients.
This study was completed in collaboration with UPMC Magee-Women’s Hospital and will e presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 – June 4th in Chicago, IL.
“…The ability to employ ML to better predict patient prognoses may help with clinical management and monitoring and could serve as a decision support tool to better tailor treatment plans to individual patients. The results of this important study strongly support continued development of such ML models and subsequent incorporation into daily clinical practice,” stated, Robert Edwards, MD, Professor and Chair, Department of Obstetrics, Gynecology & Reproductive Sciences, Co-Director, Gynecologic Oncology Research, Magee-Womens Hospital of UPMC.
Upon the announcement, shares of Predictive have traded up over 40% and currently leads the PRISM NextGen Tech and AI Index.
